J INTS BIO
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.jintsbio.com
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Phase 1
Recruiting
- Conditions
- EGFR Mutant Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- J Ints Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05394831
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, California, United States
🇰🇷Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- J Ints Bio
- Registration Number
- NCT04526717
Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies
Early Phase 1
Withdrawn
- Conditions
- Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- J Ints Bio
- Registration Number
- NCT04294875
© Copyright 2025. All Rights Reserved by MedPath